Case Report: Second-line favourable effect of pembrolizumab plus chemotherapy in a patient with metastatic hepatoid adenocarcinoma of the stomach

被引：0
作者：
Tang, Yao [1 ]
Li, Xiaofen [1 ,2 ]
Yang, Yu [1 ,2 ]
机构：
[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Canc Ctr, Div Abdominal Tumor Multimodal Treatment, Chengdu, Peoples R China
来源：
FRONTIERS IN PHARMACOLOGY | 2025年 / 16卷
关键词：
hepatoid adenocarcinoma of the stomach(HAS); case report; pembrolizumab; chemotherapy; immunotherapy; GASTRIC-CANCER; FEATURES; CARCINOMA;
D O I：
10.3389/fphar.2025.1387661
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Hepatoid adenocarcinoma of the stomach (HAS) is a rare and aggressive malignancy with poor prognosis. HAS is characterized by both adenocarcinoma and hepatocellular carcinoma like differentiation, which often produces alpha-fetoprotein (AFP) and responds poorly to systemic chemotherapy. Herein we report a case of 62-year-old male diagnosed with liver metastatic HAS, who progressed rapidly after first-line cisplatin + fluorouracil chemotherapy combined with pembrolizumab. However, the patient achieved favourable outcome after second-line oxaliplatin + capecitatine chemotherapy combined with pembrolizumab. This case indicated that the chemotherapy regimen might influence the efficacy of immune check-point inhibiors plus chemotherapy.
引用
收藏
页数：6
相关论文
共 33 条
[1]   Gastric Cancer, Version 2.2022 [J].
Ajani, Jaffer A. ;
D'Amico, Thomas A. ;
Bentrem, David J. ;
Chao, Joseph ;
Cooke, David ;
Corvera, Carlos ;
Das, Prajnan ;
Enzinger, Peter C. ;
Enzler, Thomas ;
Fanta, Paul ;
Farjah, Farhood ;
Gerdes, Hans ;
Gibson, Michael K. ;
Hochwald, Steven ;
Hofstetter, Wayne L. ;
Ilson, David H. ;
Keswani, Rajesh N. ;
Kim, Sunnie ;
Kleinberg, Lawrence R. ;
Klempner, Samuel J. ;
Lacy, Jill ;
Ly, Quan P. ;
Matkowskyj, Kristina A. ;
McNamara, Michael ;
Mulcahy, Mary F. ;
Outlaw, Darryl ;
Park, Haeseong ;
Perry, Kyle A. ;
Pimiento, Jose ;
Poultsides, George A. ;
Reznik, Scott ;
Roses, Robert E. ;
Strong, Vivian E. ;
Su, Stacey ;
Wang, Hanlin L. ;
Wiesner, Georgia ;
Willett, Christopher G. ;
Yakoub, Danny ;
Yoon, Harry ;
McMillian, Nicole ;
Pluchino, Lenora A. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (02) :167-192
[2]  
BOURREILLE J, 1970, PRESSE MED, V78, P1277
[3]  
CHANG YC, 1990, AM J GASTROENTEROL, V85, P1480
[4]   Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis [J].
Dall'Olio, Filippo Gustavo ;
Rizzo, Alessandro ;
Mollica, Veronica ;
Massucci, Maria ;
Maggio, Ilaria ;
Massari, Francesco .
IMMUNOTHERAPY, 2021, 13 (03) :257-270
[5]   The Effectiveness of Hepatic Arterial Infusion Chemotherapy with 5-Fluorouracil/Cisplatin and Systemic Chemotherapy with Ramucirumab in Alpha-Fetoprotein-Producing Gastric Cancer with Multiple Liver Metastases [J].
Doi, Yasuhiro ;
Takii, Yasushi ;
Mitsugi, Kenji ;
Kimura, Koichi ;
Mihara, Yutarou .
CASE REPORTS IN ONCOLOGICAL MEDICINE, 2018, 2018
[6]   Preliminary study on the clinical and pathological relevance of gastric hepatoid adenocarcinoma [J].
Gao, Ya Bo ;
Zhang, Ding Fang ;
Jin, Xiao Long ;
Xiao, Jia Cheng .
JOURNAL OF DIGESTIVE DISEASES, 2007, 8 (01) :23-28
[7]   The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis [J].
Guven, Deniz Can ;
Sahin, Taha Koray ;
Erul, Enes ;
Rizzo, Alessandro ;
Ricci, Angela Dalia ;
Aksoy, Sercan ;
Yalcin, Suayib .
FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
[8]   Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy [J].
Hao, Yuhao ;
Li, Rui ;
Pan, Wen ;
Tian, Shaomin ;
Min, Yuanzeng .
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (17) :12225-12236
[9]   Gastrointestinal hepatoid adenocarcinoma: Venous permeation and mimicry of hepatocellular carcinoma, a report of four cases [J].
Ishikura, H ;
Kishimoto, T ;
Andachi, H ;
Kakuta, Y ;
Yoshiki, T .
HISTOPATHOLOGY, 1997, 31 (01) :47-54
[10]  
ISHIKURA H, 1985, CANCER-AM CANCER SOC, V56, P840, DOI 10.1002/1097-0142(19850815)56:4<840::AID-CNCR2820560423>3.0.CO
1234